Hypertrophic Scar/Keloids

CTGF is a major factor in fibrotic diseases which promotes the production of extracellular matrix (ECM) proteins, including collagen.
Often, abnormal response (production of extra collagen fibers due to overexpression of CTGF) during the wound healing process leads to the formation of hypertrophic scars/keloids.

Development Status

• Efficient inhibition of fibrosis identified in animal models
• Phase 1 clinical trial completed (US, UK)

• 제목	링크
  A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers	Learn More
  A Phase 1, Single Center, Placebo-controlled, Interventional Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles in Healthy Subjects Compared to Placebo	Learn More

• Phase 2 clinical trial in progress (Korea, US)

• Title	Link
  An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar	Learn More
  Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery	Learn More

Conference Presentation

• 2016 Journal of Investigative Dermatology

• Title	Download
  Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313.	PDF Download

• 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)